Anika to Showcase Commercial and Pipeline Portfolio at 2018 AAOS Annual Meeting
March 06 2018 - 7:00AM
Anika Therapeutics, Inc. (NASDAQ:ANIK), a global, integrated
orthopedics medicines company specializing in therapeutics based on
its proprietary hyaluronic acid ("HA") technology, today announced
plans to showcase its innovative commercial and pipeline portfolio
at the 2018 American Academy of Orthopaedic Surgeons (AAOS) Annual
Meeting, being held in New Orleans on March 6 – 10, 2018. Anika’s
appearance at the world’s largest meeting of orthopedic surgeons,
researchers and allied health professionals, will feature an
educational workshop on HYALOFAST® and product and technology
demonstrations at its AAOS exhibit booth #6933.
“We’re excited to attend the 2018 AAOS Annual Meeting to
showcase our expansive orthopedic product portfolio, and
proprietary HA-based technologies which fuel our thriving R&D
pipeline,” said Joseph Darling, President and newly named CEO of
Anika Therapeutics. “AAOS coincides with a transformational
time for Anika as we build our direct commercialization operations
to support the launch of our innovative combination
viscosupplement, CINGAL®, and accelerate our clinical development
and R&D efforts to yield a series of commercial, regulatory and
clinical milestones over the next 12 to 18 months. We look forward
to introducing Anika and its portfolio to the 30,000-plus members
of the global orthopedic surgery community at AAOS, and forging
relationships with key stakeholders who will be critical to the
success of our direct sales and marketing efforts.”
Below are highlights of Anika’s planned activities at the 2018
AAOS Annual Meeting:
- Anika Exhibit Booth #6933
- Bioskills Workshop on HYALOFAST, Wednesday, March 7th from
5:30-8:30 p.m. in Lab 3 at the AAOS Conference Center. This
workshop is open to all registered AAOS Meeting attendees.
“Our participation in the 2018 AAOS Annual Meeting represents an
important opportunity for Anika to engage U.S. orthopedic medicine
thought-leaders about CINGAL, and showcase both real-world evidence
from its successful launches overseas and clinical evidence from
the first CINGAL Phase III study, to validate its benefits and
advantages over currently available single-agent viscosupplements,”
said Joseph Darling.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ:ANIK) is
a global, integrated orthopedic medicines company based
in Bedford, Massachusetts. Anika is committed to improving the
lives of patients with degenerative orthopedic diseases and
traumatic conditions with clinically meaningful therapies along the
continuum of care, from palliative pain management to regenerative
tissue repair. The Company has over two decades of global expertise
developing, manufacturing, and commercializing more than 20
products based on its proprietary hyaluronic acid (HA)
technology. Anika's orthopedic medicine portfolio
includes ORTHOVISC®, MONOVISC®,
and CINGAL, which alleviate pain and restore
joint function by replenishing depleted HA,
and HYALOFAST, a solid HA-based scaffold to
aid cartilage repair and regeneration. For more information about
Anika, please
visit www.anikatherapeutics.com.
For Investor Inquiries: Anika Therapeutics, Inc. Sylvia Cheung,
781-457-9000 Chief Financial Officer |
For Media Inquiries: Pure Communications Sonal Vasudev,
917-523-1418, sonal@purecommunicationsinc.com |
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Apr 2023 to Apr 2024